<h3>享受 TipRanks Premium 50% 折扣，放心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>来自先声药业（HK:2096）的最新更新已发布。</p>
<p>先声药业已获得中国国家药品监督管理局的批准，开始针对局部晚期或转移性实体瘤患者的独立开发的双特异性抗体药物结合物 SIM0610 的临床试验。SIM0610 旨在通过细胞内释放拓扑异构酶 I 抑制剂诱导肿瘤细胞凋亡，并解决药物耐受机制，特别是对 EGFR 酪氨酸激酶抑制剂的耐药性；前临床数据已显示在多个肿瘤模型中具有显著的抗肿瘤活性，突显了先声在加强其肿瘤学管线和在靶向癌症治疗中的竞争地位方面的努力。</p>
<p>（HK:2096）股票的最新分析师评级为买入，目标价为 16.30 港元。要查看先声药业股票的完整分析师预测列表，请参见 HK:2096 股票预测页面。</p>
<p><strong>关于先声药业的更多信息</strong></p>
<p>先声药业是一家以创新和研发为驱动的制药公司，已建立国家重点神经病学和肿瘤药物开发实验室。它专注于神经科学、肿瘤学、自身免疫疾病和抗感染领域的治疗，并在具有显著未来临床需求的疾病领域追求前瞻性发展，得益于内部研究和与创新公司及研究机构的战略合作。</p>
<p><strong>平均交易量：</strong> 8,403,511</p>
<p><strong>技术情绪信号：</strong> 买入</p>
<p><strong>当前市值：</strong> 340.3 亿港元</p>

先声药业

<p>先声药业集团有限公司已获得中国国家药品监督管理局的批准，开始针对 SIM0610 的临床试验，这是一种针对 EGFR 和 cMET 的新型癌症药物。该双特异性抗体药物偶联物旨在诱导肿瘤细胞凋亡并解决药物耐药性。临床前数据表明其具有显著的抗肿瘤活性，增强了先声药业的肿瘤学产品线。该股票评级为 “买入”，目标价为 16.30 港元</p>

<h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，放心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>The latest update is out from Simcere Pharmaceutical Group Limited ( (HK:2096) ).</p>
<div class="lb-trans"><p>来自先声药业（HK:2096）的最新更新已发布。</p>
</div><p>Simcere Pharmaceutical Group Limited has received approval from China’s National Medical Products Administration to begin clinical trials for SIM0610, an independently developed bispecific antibody-drug conjugate targeting EGFR and cMET in patients with locally advanced or metastatic solid tumors. SIM0610 is designed to induce tumor cell apoptosis via intracellular release of a topoisomerase I inhibitor and to address drug resistance mechanisms, particularly resistance to EGFR tyrosine kinase inhibitors; preclinical data have shown significant anti-tumor activity across multiple tumor models, underscoring Simcere’s push to strengthen its oncology pipeline and competitive position in targeted cancer therapies.</p>
<div class="lb-trans"><p>先声药业已获得中国国家药品监督管理局的批准，开始针对局部晚期或转移性实体瘤患者的独立开发的双特异性抗体药物结合物 SIM0610 的临床试验。SIM0610 旨在通过细胞内释放拓扑异构酶 I 抑制剂诱导肿瘤细胞凋亡，并解决药物耐受机制，特别是对 EGFR 酪氨酸激酶抑制剂的耐药性；前临床数据已显示在多个肿瘤模型中具有显著的抗肿瘤活性，突显了先声在加强其肿瘤学管线和在靶向癌症治疗中的竞争地位方面的努力。</p>
</div><p>The most recent analyst rating on (HK:2096) stock is a Buy with a HK$16.30 price target. To see the full list of analyst forecasts on Simcere Pharmaceutical Group Limited stock, see the HK:2096 Stock Forecast page.</p>
<div class="lb-trans"><p>（HK:2096）股票的最新分析师评级为买入，目标价为 16.30 港元。要查看先声药业股票的完整分析师预测列表，请参见 HK:2096 股票预测页面。</p>
</div><p><strong>More about Simcere Pharmaceutical Group Limited</strong></p>
<div class="lb-trans"><p><strong>关于先声药业的更多信息</strong></p>
</div><p>Simcere Pharmaceutical Group Limited is an innovation- and R&amp;D-driven pharmaceutical company that has established a State Key Laboratory of Neurology and Oncology Drug Development. It focuses on therapies in neuroscience, oncology, autoimmune diseases and anti-infective areas, and pursues forward-looking development in disease areas with significant future clinical needs, supported by in-house research and strategic partnerships with innovative companies and research institutes.</p>
<div class="lb-trans"><p>先声药业是一家以创新和研发为驱动的制药公司，已建立国家重点神经病学和肿瘤药物开发实验室。它专注于神经科学、肿瘤学、自身免疫疾病和抗感染领域的治疗，并在具有显著未来临床需求的疾病领域追求前瞻性发展，得益于内部研究和与创新公司及研究机构的战略合作。</p>
</div><p><strong>Average Trading Volume:</strong> 8,403,511</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 8,403,511</p>
</div><p><strong>Technical Sentiment Signal:</strong> Buy</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 买入</p>
</div><p><strong>Current Market Cap:</strong> HK$34.03B</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 340.3 亿港元</p>
</div>

先声药业获得国家药品监督管理局（NMPA）的批准，开始进行新型 EGFR/cMET 癌症药物的临床试验